Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS ...

Corcept Therapeutics (CORT.O), opens new tab said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal ...

Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from ...

Corcept is studying it as a potential treatment for ALS and other neurologic disorders. Dazucorilant is proprietary to Corcept and is protected by composition of matter, method of use and other ...